Serum Elabela Level Significantly Increased in Patients with Complete Heart Block
Armağan Acele1, Atilla Bulut1, Yurdaer Donmez1
1Adana Health Practice and Research Center University of Health Sciences Department of Cardiology Adana Turkey Department of Cardiology, University of Health Sciences - Adana Health Practice and Research Center, Adana, Turkey.
Insights
Serum Elabela levels are significantly higher in patients with complete atrioventricular (AV) block. This new peptide may aid in the early detection of AV block, a condition often requiring pacemaker implantation.
Area of Science:
- Cardiology
- Biochemistry
- Peptide Research
Background:
- The apelinergic system plays a role in cardiovascular regulation.
- Elabela is a newly identified peptide within the apelinergic system.
- Complete atrioventricular (AV) block significantly impacts cardiac function and often necessitates pacemaker implantation.
Purpose of the Study:
- To investigate serum Elabela levels in patients with complete AV block compared to healthy controls.
- To explore the correlation of Elabela levels with cardiac function parameters and inflammatory markers.
- To assess the diagnostic potential of Elabela for identifying complete AV block.
Main Methods:
- Serum Elabela levels were measured in 50 patients with complete AV block scheduled for pacemaker implantation and 50 healthy controls.
- Routine clinical data, physical examinations, and laboratory tests were collected.
- Statistical analyses, including correlation and linear regression, were performed.
Main Results:
- Patients with AV block exhibited significantly higher serum Elabela levels, lower heart rate, and reduced cardiac output compared to controls.
- Serum Elabela levels correlated positively with high-sensitive C-reactive protein and NT-proBNP, and negatively with heart rate and cardiac output.
- An Elabela level > 9.5 ng/ml demonstrated high sensitivity (90.2%) and specificity (88.0%) for detecting complete AV block.
Conclusions:
- Serum Elabela levels are elevated in patients with complete AV block prior to pacemaker implantation.
- Serum Elabela shows potential as a biomarker for the early determination of complete AV block.
- Further research is warranted to elucidate the precise role of Elabela in AV block pathophysiology.
Objective:
To investigate the change in serum Elabela level, a new apelinergic system peptide, in patients with complete atrioventricular (AV) block and healthy controls.
Methods:
The study included 50 patients with planned cardiac pacemaker (PM) implantation due to complete AV block and 50 healthy controls with similar age and gender. Elabela level was measured in addition to routine anamnesis, physical examination, and laboratory tests. Patients were divided into two groups, with and without AV block, and then compared.
Results:
In patients with AV block, serum Elabela level was significantly higher and heart rate and cardiac output were significantly lower than in healthy controls. Serum Elabela level was found to be positively correlated with high-sensitive C-reactive protein and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, but negatively correlated with heart rate, high-density lipoprotein cholesterol, and cardiac output. In linear regression analysis, it was found that these parameters were only closely related to heart rate and NT-proBNP. Serum Elabela level was determined in the patients with AV block independently; an Elabela level > 9.5 ng/ml determined the risk of complete AV-block with 90.2% sensitivity and 88.0% specificity.
Conclusion:
In patients with complete AV block, the serum Elabela level increases significantly before the PM implantation procedure. According to the results of our study, it was concluded that serum Elabela level could be used in the early determination of patients with complete AV block.
More Related Videos
Related Concept Videos
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Heart Failure III: Clinical Manifestations
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Dysrhythmias V: Evaluating Dysrhythmias
Heart Failure II: Pathophysiology


